A-S Medication Solutions

Pharmaunternehmen56 erfasste Produkte

erfasste Produkte

3.447.028

Meldungen insgesamt

425

dokumentierte Rückrufe

65,4%

schwerwiegend insgesamt

Produkte

56 von 56 angezeigt

Produkt	Zugelassen	Meldungen ↓	Top-Signal	Rückrufe
prednisone —	1972	491.157	Systemischer Lupus erythematodes	11
levothyroxine sodium —	2000	308.680	Herzklopfen	100
ibuprofen capsules 200 mg —	—	195.145	Chronische Nierenerkrankung	1
montelukast —	2012	171.338	Asthma	14
naproxen —	1987	162.981	Gelenkentzündung	12
spironolactone —	1979	137.410	Hyperkaliämie	11
levetiracetam —	2003	130.496	Resistenz gegen mehrere Medikamente	18
celecoxib —	1998	129.432	Psoriasis-Arthropathie	4
diazepam —	1963	119.417	Drogenmissbrauch	13
montelukast sodium —	2012	118.894	Atemwegsobstruktion	14
formoterol fumarate dihydrate —	2006	114.158	Atemwegsobstruktion	2
amoxicillin —	1974	99.955	Nierenversagen im Endstadium	20
tadalafil —	2019	98.103	Pulmonale arterielle Hypertonie	0
budesonide and formoterol fumarate dihydrate —	—	95.176	Atemwegsobstruktion	1
dulaglutide —	2014	86.770	Versehentliche Unterdosierung	3
emtricitabine —	2015	77.542	Knochendemineralisierung	3
carbamazepine —	1986	66.038	Epilepsie	12
insulin aspart —	2000	64.485	Verminderter Blutzucker	5
metronidazole —	1982	63.743	Clostridium-difficile-Infektion	15
letrozole —	1997	60.586	Metastasierender Brustkrebs	2
fluticasone propionate and salmeterol xinafoate —	—	59.089	Atemwegsobstruktion	0
dapagliflozin —	2014	56.693	Diabetische Ketoazidose	1
tenofovir alafenamide —	2015	41.643	Knochendemineralisierung	0
naltrexone —	1984	39.971	Alkoholabhängigkeit	17
insulin detemir —	2005	38.856	Erhöhter Blutzucker	1
emtricitabine and tenofovir alafenamide —	—	35.132	Knochendemineralisierung	0
fenofibrate —	2001	34.581	Chronische Nierenerkrankung	11
canagliflozin —	2013	30.943	Infektion des diabetischen Fusses	1
amoxicillin and clavulanate potassium —	—	26.702	Cholestase	5
atomoxetine —	2002	26.564	Lidkrampf	19
azelastine —	2000	21.326	Problem mit dem Produktabgabemechanismus	9
cephalexin —	1971	21.106	Nephrogene Anämie	24
cobicistat —	2012	20.686	Zahnverletzung	0
moxifloxacin —	2001	19.663	Keuchender Atem	38
moxifloxacin hydrochloride —	2001	19.655	Keuchender Atem	0
desoximetasone —	1980	18.541	Anti-zyklisch-citrullinierte Peptid-Antikörper positiv	13
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate —	—	17.624	Verminderte Knochendichte	0
amitriptyline hydrochloride —	1977	16.938	Schmerzen an der Infusionsstelle	0
trazodone hydrochloride —	1981	15.321	Suizidversuch	0
thyroid, porcine —	—	10.359	Herzklopfen	0
azelastine hydrochloride —	2000	10.154	Problem mit dem Produktabgabemechanismus	4
naltrexone hydrochloride —	1984	9.868	Unzufriedenheit des Patienten mit der Behandlung	1
beclomethasone dipropionate —	1976	9.839	Nasenbeschwerden	7
colesevelam hydrochloride —	2000	9.134	Kein unerwünschtes Ereignis	0
triazolam —	1982	8.566	Sopor	0
etodolac —	1996	5.914	Chronische Nierenerkrankung	2
betamethasone valerate —	1967	4.388	Vaginale Blähungen	0
clindamycin hydrochloride —	1970	3.461	Makulopapulöser Ausschlag	3
sodium zirconium cyclosilicate —	2018	3.424	Abnormaler Kaliumwert im Blut	0
clindamycin phosphate topical —	—	3.384	Hidradenitis	5
cefuroxime axetil —	1987	3.377	Lymphödem	0
levalbuterol hydrochloride —	1999	3.293	Asthma	0
norethindrone acetate and ethinyl estradiol and ferrous fumarate —	—	2.865	Metrorrhagie	0
beclomethasone dipropionate hfa —	—	2.734	Problem mit dem Verabreichungssystem des Geräts	3
insulin lispro-aabc —	2020	1.984	Reizung an der Infusionsstelle	0
darunavir ethanolate and cobicistat —	—	1.744	Knochendemineralisierung	0

Rückrufhistorie · 50 dokumentiert

Datum	Klasse	Grund	Firma
28. Mai 2026	II	CGMP Deviations	Ajanta Pharma USA Inc
30. Apr. 2026	II	Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.	Safecor Health, LLC
20. Apr. 2026	II	Chemical contamination; presence of lead and lithium above specification	Acella Pharmaceuticals, LLC
26. Feb. 2026	II	Subpotent Drug	MACLEODS PHARMA USA, INC
31. Dez. 2025	II	Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.	Alvogen, Inc
18. Dez. 2025	II	Presence of particulate matter - Glass like particles.	Imprimis NJOF, LLC
13. Okt. 2025	II	Subpotent drug; Clavulanate Potassium component	Teva Pharmaceuticals USA, Inc
15. Sept. 2025	II	Failed Dissolution Specifications.	Amerisource Health Services LLC
5. Aug. 2025	II	Presence of foreign substance: identified as aluminum.	SUN PHARMACEUTICAL INDUSTRIES INC
29. Juli 2025	II	Subpotent drug	Pfizer
20. Juni 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20. Juni 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20. Juni 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20. Juni 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20. Juni 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
28. Mai 2025	II	Lack of Assurance of Sterility	Apotex Corp.
23. Mai 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
23. Mai 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
13. Mai 2025	II	Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules	AvKARE
9. Mai 2025	II	Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule	Alembic Pharmaceuticals Limited
10. Apr. 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
10. Apr. 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
13. März 2025	I	LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.	Dr. Reddy's Laboratories, Inc.
13. März 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
13. März 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
7. März 2025	II	Super-Potent Drug: Out of specification potency results were obtained.	Mylan Institutional, Inc.
25. Feb. 2025	II	Presence of Foreign Tablets/Capsules.	A-S Medication Solutions LLC
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29. Jan. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
20. Dez. 2024	II	Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.	Lupin Pharmaceuticals Inc.
19. Nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19. Nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19. Nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19. Nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19. Nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19. Nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
18. Nov. 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc
18. Nov. 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc

Klasse I = begründete Wahrscheinlichkeit schwerwiegender Schäden · Klasse II = vorübergehend oder reversibel · Klasse III = Schaden unwahrscheinlich.

Registrierungsstatus

Einige Produkte von A-S Medication Solutions sind nicht für die Anwendung am Menschen FDA-registriert. Für nicht registrierte Substanzen (Peptide, SARMs ohne Humanzulassung) existiert kein legitimer Anbieter für die Anwendung am Menschen. Das Fehlen eines Bezugswegs ist die Sicherheitsinformation.